123 related articles for article (PubMed ID: 21878970)
21. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
[TBL] [Abstract][Full Text] [Related]
22. Genentech's anticancer Mab expected by November.
Robertson D
Nat Biotechnol; 1998 Jul; 16(7):615. PubMed ID: 9661186
[No Abstract] [Full Text] [Related]
23. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Dalmases A; Rojo F; Rovira A; Albanell J
Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
[No Abstract] [Full Text] [Related]
24. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
25. The distinctive nature of HER2-positive breast cancers.
Burstein HJ
N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
[No Abstract] [Full Text] [Related]
26. Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics.
Hennessy BT; Gonzalez-Angulo AM; Hortobagyi GN
Nat Clin Pract Oncol; 2005 Dec; 2(12):598-9. PubMed ID: 16341096
[No Abstract] [Full Text] [Related]
27. Trastuzumab in the treatment of breast cancer.
Hortobagyi GN
N Engl J Med; 2005 Oct; 353(16):1734-6. PubMed ID: 16236745
[No Abstract] [Full Text] [Related]
28. Trastuzumab in breast cancer.
Gounaris IG
N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470950
[No Abstract] [Full Text] [Related]
29. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
Burstein HJ; Sun Y; Dirix LY; Jiang Z; Paridaens R; Tan AR; Awada A; Ranade A; Jiao S; Schwartz G; Abbas R; Powell C; Turnbull K; Vermette J; Zacharchuk C; Badwe R
J Clin Oncol; 2010 Mar; 28(8):1301-7. PubMed ID: 20142587
[TBL] [Abstract][Full Text] [Related]
30. [Breast cancer: adjuvant therapy with trastuzumab: herceptin adjuvant (HERA) Trial Study, B-31- and N9831-Study].
Mallmann P
Internist (Berl); 2006 Nov; 47(11):1183-5. PubMed ID: 17048017
[No Abstract] [Full Text] [Related]
31. Can strategies targeting cleaved MUC1 overcome resistance to trastuzumab?
Araki K; Pegram M
Breast Cancer Res Treat; 2011 Jun; 127(2):589-90. PubMed ID: 19834800
[No Abstract] [Full Text] [Related]
32. Herceptin in early breast cancer: a call for judicious use.
Thorat MA
Natl Med J India; 2005; 18(6):315-7. PubMed ID: 16483033
[No Abstract] [Full Text] [Related]
33. 5. Tanstuzumab treatment for breast cancer.
Hatake K; Tokudome N; Ito Y
Intern Med; 2007; 46(3):149-50. PubMed ID: 17268136
[No Abstract] [Full Text] [Related]
34. [Adjuvant chemotherapy for breast cancer and targeted therapies].
Dufresne A; Bachelot T; Blay JY
Rev Prat; 2008 Mar; 58(5):477-8. PubMed ID: 18524101
[No Abstract] [Full Text] [Related]
35. [Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene?].
Beuzeboc P; Scholl S; Garau XS; Vincent-Salomon A; Cremoux PD; Couturier J; Palangié T; Pouillart P
Bull Cancer; 1999 Jun; 86(6):544-9. PubMed ID: 10417428
[TBL] [Abstract][Full Text] [Related]
36. PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough.
Hynes NE; Dey JH
Cancer Cell; 2009 May; 15(5):353-5. PubMed ID: 19411062
[TBL] [Abstract][Full Text] [Related]
37. Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
Seidman AD
Nat Clin Pract Oncol; 2006 Apr; 3(4):178-9. PubMed ID: 16596138
[No Abstract] [Full Text] [Related]
38. HER-2 inhibitors: clinical results.
Crinò L; Franceschi E; Scopece L
Suppl Tumori; 2002; 1(6):S3-4. PubMed ID: 12658892
[No Abstract] [Full Text] [Related]
39. Making real progress against breast cancer. Some of the best cancer news this year has been the success of targeted approaches to treating breast cancer.
Harv Womens Health Watch; 2005 Oct; 13(2):1-3. PubMed ID: 16320417
[No Abstract] [Full Text] [Related]
40. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
Baselga J; Swain SM
Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]